| 证券代码 | NEOS.O |
| 证券名称 | Neos Therapeutics Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2015-07-23 |
| 首发价格(元) | 15 USD |
| 首发数量(股) | 4800000 |
| 首发募资额(元) | 72,000,000.00 USD |
| 首发主承销商 | BMO Capital Markets Corp,RBC Capital Markets, LLC,UBS Investment |
| 货币单位 | USD |
| 公司名称 | Neos Therapeutics, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 2940 N. Highway 360, Grand Prairie, Texas, USA |
| 成立日期 | 1994-11-30 |
| 董事会主席 | Alan L. Heller |
| 公司属地 | United States 美国 |
| 公司网址 | www.neostx.com |
| 电话 | +1 (972) 408-1300 |
| 传真 | +1 (972) 408-1143 |
| 公司简介 | Neos Therapeutics, Inc. (NASDAQ: NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT(methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER(amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex(1), an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold (see Full Prescribing Information, including Boxed WARNING). |